All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
FELIX trial: Obe-cel for R/R B-ALL
Do you know... In the FELIX trial (phase II, Cohort A), what was the overall remission (complete remission or complete remission with incomplete hematologic recovery) among patients who received obe-cel?
Obecabtagene autoleucel (obe-cel) is an autologous, anti-CD19 CAR T-cell therapy that is approved for the treatment of adults with R/R B-ALL, based on promising outcomes from the FELIX trial. The FELIX phase I/II, multicenter, single-arm study evaluated the safety and efficacy of obe-cel in adults with R/R B-ALL. Results from the FELIX trial showed obe-cel was associated with durable responses, with a low incidence of Grade ≥3 immune-related toxic effects. Furthermore, obe-cel treatment induces a high incidence of MRD-negative remission (<10⁻⁶ leukemic cells), which predicts better clinical outcomes and supports its use in adults with R/R B-ALL.
This educational resource is independently supported by Autolus. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your perception of incorporating blinatumomab into upfront ALL treatment regimens alongside traditional chemotherapy and pegaspargase?
